Sarepta inventory nuked by FDA outlook
res of Sarepta Therapeutics nearly halved on Thursday after the meals and Drug management maintained its “poor” outlook on the employer‘s drug for an extraordinary muscle-wasting ailment. Sarepta stock closed down more than forty four percentage. Sarepta is seeking out